
Biofrontera Inc. Common Stock
BFRI
BFRI: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
moreShow BFRI Financials
Recent trades of BFRI by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BFRI's directors and management
Government lobbying spending instances
-
$5,000 Jul 11, 2019 Issue: Health Issues
-
$5,000 Apr 16, 2019 Issue: Health Issues
-
$5,000 Jan 11, 2019 Issue: Health Issues
-
$5,000 Oct 19, 2018 Issue: Health Issues
New patents grants
Federal grants, loans, and purchases
Followers on BFRI's company Twitter account
Number of mentions of BFRI in WallStreetBets Daily Discussion
Recent insights relating to BFRI
Recent picks made for BFRI stock on CNBC
ETFs with the largest estimated holdings in BFRI
Flights by private jets registered to BFRI